14-May-2015 08:12 AM
Hikma Pharmaceuticals has reiterated its full year guidance for the group and each of its business segments after making a good start to the year.
Shareholders at today annual general meeting will be told that the group expects full year revenue growth o
12-May-2015 09:07 AM
Hikma Pharmaceuticals has launched CAFCIT Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL).
CAFCIT is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.
Chairman and chief e
11-Mar-2015 08:41 AM
Hikma Pharmaceuticals reports an excellent performance in 2014 with strong underlying growth.
Group revenue for the year to the end of December increased by 9% to $1,489m, driven by strong growth in Injectables.
Profit attributable to shareholders incr
27-Jan-2015 02:35 PM
Hikma Pharmaceuticals joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on 21-24 January, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab
12-Jan-2015 07:42 AM
Hikma Pharmaceuticals notes that Takeda Pharmaceuticals USA. Inc has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the
06-Nov-2014 09:07 AM
Hikma Pharmaceuticals reports a strong performance in its Injectables, Branded and Generics businesses and has raised its guidance for 2014 group revenue growth of around 7%.
The group says its financing position remains very strong and will enable it
24-Oct-2014 07:16 AM
Hikma Pharmaceuticals has received a 'warning letter' from the US Food and Drug Administration related to the inspection of its manufacturing facility in Portugal in March.
In the letter, the agency raised issues related to investigations and
01-Oct-2014 07:26 AM
Hikma Pharmaceuticals has received approval of its new drug application for colchicine 0.6mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE.
MITIGARE is indicated for prophylaxis of gout
17-Sep-2014 07:34 AM
Hikma Pharmaceuticals has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, part of the Boehringer Ingelheim Group of Companies, as agreed on 24 July . The Ben Venue sit
20-Aug-2014 08:23 AM
Hikma Pharmaceuticals reports an excellent first half with 16% revenue growth and a 44% increase in adjusted earnings per share.
Hikma said group revenue increased by 16% to $738m, driven by the very strong performance of its Injectables business in t
24-Jul-2014 09:14 AM
Hikma Pharmaceuticals agreed with Ben Venue Laboratories - part of the Boehringer Ingelheim Group - to acquire substantially all of its generic injectables manufacturing site in Bedford, Ohio.
The acquisition is pursuant to the exclusivity arrangement
15-Jul-2014 04:02 PM
Hikma Pharmaceuticals has completed its acquisition of assets of the US generic injectables business, Bedford Laboratories from Ben Venue Laboratories, a member of the Boehringer Ingelheim Group of Companies.
As previously announced, the total consider
28-May-2014 12:12 PM
Hikma Pharmaceuticals (LSE: HIK), the multinational pharmaceutical group, has signed an asset purchase agreement with Ben Venue Laboratories, a member of the Boehringer Ingelheim Group of Companies, to acquire assets of Bedford Laboratories, its US generi
15-May-2014 08:25 AM
Hikma Pharmaceuticals has made a strong start to the year and is reiterating its guidance for 2014 of around 5% group revenue growth, following an exceptionally strong year in 2013.
Chief executive Said Darwazah said: "Our efforts to build a broad
02-Apr-2014 08:27 AM
Hikma Pharmaceuticals says it has resolved issues raised by the US Food and Drug Administration in February 2012.
Hikma says it has received a close-out letter from the FDA that lifts the warning letter about the Eatontown facility in New Jersey, which
12-Mar-2014 08:24 AM
Hikma Pharmaceuticals has announced changes to its board composition and organisational structure. Mazen Darwazah is to be promoted to the new position of president and chief executive of MENA and emerging markets. Darwazah's additional responsibi
12-Mar-2014 07:26 AM
Hikma Pharmaceuticals said it delivered an excellent performance in 2013 with revenue growth of 23% and EPS up 111%. Profit attributable to shareholders increased by 112% to $212m in the year to end-December.
Hikma said it expects continued growth in 20
11-Feb-2014 02:37 PM
Hikma Pharmaceuticals has unveiled a raft of board changes which will take effect from the annual general meeting on 15 May.
Non-executive chairman Samih Darwazah will retire from the board and become honorary life president while chief executive Said
20-Nov-2013 08:16 AM
Hikma Pharmaceuticals has signed a long term commercial supply contract with Unilife Corporation for the use of Unifill prefilled syringes with a range of generic injectable drugs. Under the 15-year global agreement, Unilife will supply Hikma with custo
08-Nov-2013 07:39 AM
Hikma Pharmaceuticals' 'injectables; business is delivering an excellent performance and the group is encouraged by the significant opportunities the US market continues to offer.
The group says its financing position remains very strong and w
18-Sep-2013 08:09 AM
Hikma Pharmaceuticals has signed a 50:50 joint venture agreement with MIDROC Pharmaceuticals, a member of Sheikh Mohammed Hussein Al Amoudi's MIDROC Group, to establish a presence in the Ethiopian pharmaceutical market.
The JV will be called Hikm
21-Aug-2013 07:47 AM
Hikma reports exceptionally strong first half results with revenues up nearly 20% and a 156% increase in adjusted earnings per share.
Group revenue increased by 19.9% to $638.3m and full year group guidance has been raised to around 20% revenue growth.
21-Aug-2013 07:30 AM
Hikma Phrmaceutical said today it delivered exceptionally strong first half results with 20% revenue growth and a 156% increase in adjusted EPS.
The group raised guidance to around 20% revenue growth for the full year, with a positive outlook for all bu
08-Jul-2013 07:06 AM
Hikma Pharmaceuticals said all of its businesses have continued to perform well. The Branded business remains on track to achieve around 9% revenue growth.
The Generics business has continued to benefit from strong doxycycline sales. Given the
01-Jul-2013 07:49 AM
Hikma Pharmaceuticals has signed an exclusive commercialisation agreement with Theravance for VIBATIV (telavancin) in the Middle East and North Africa region.
VIBATIV is a bactericidal, once-daily lipoglycopeptideinjectable antibiotic for Gram-positiv